EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Atrophin‐1 Function and Dysfunction in Dentatorubral–Pallidoluysian Atrophy

Bartosz Nowak, Emilia Kozlowska, Weronika Pawlik, Agnieszka Fiszer iD

Movement Disorders · 2023-04 · 38 (4) · 526-536

DOI: 10.1002/mds.29355 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Movement Disorders, online erschienen am 21.02.2023. Verfasst von Bartosz Nowak und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biotechnology, Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland. Hauptthemen laut MEDLINE: Cerebellar Ataxia, Myoclonic Epilepsies, Progressive. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerstwo Edukacji i Nauki, Narodowe Centrum Nauki.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dentatorubral–pallidoluysian atrophy (DRPLA) is a rare, incurable genetic disease that belongs to the group of polyglutamine (polyQ) diseases. DRPLA is the most common in the Japanese population; however, its global prevalence is also increasing due to better clinical recognition. It is characterized by cerebellar ataxia, myoclonus, epilepsy, dementia, and chorea. DRPLA is caused by dynamic mutation of CAG repeat expansion in ATN1 gene encoding the atrophin‐1 protein. In the cascade of molecular disturbances, the pathological form of atrophin‐1 is the initial factor, which has not been precisely characterized so far. Reports indicate that DRPLA is associated with disrupted protein–protein interactions (in which an expanded polyQ tract plays a crucial role), as well as gene expression deregulation. There is a great need to design efficient therapy that would address the underlying neurodegenerative process and thus prevent or alleviate DRPLA symptoms. An in‐depth understanding of the normal atrophin‐1 function and mutant atrophin‐1 dysfunction is crucial for this purpose. © 2024 Institute of Bioorganic Chemistry Polish Academy of Sciences. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cerebellar AtaxiaMyoclonic Epilepsies, ProgressiveHumansAtrophyMutationNerve Tissue Proteins

Stichwörter der Autor:innen

CAG repeatsatrophin-1dentatorubral-pallidoluysian atrophyneurodegenerationpolyglutamine diseases

Substanzen

atrophin-1Nerve Tissue Proteins

Autor:innen und Institutionen

  • Department of Medical Biotechnology, Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.

ORCID-Profile: Agnieszka Fiszer

Förderung

  • Ministerstwo Edukacji i Nauki
  • Narodowe Centrum Nauki

Zitieren

APA

Nowak, B., Kozlowska, E., Pawlik, W., & Fiszer, A. (2023). Atrophin‐1 Function and Dysfunction in Dentatorubral–Pallidoluysian Atrophy. Movement Disorders, 38(4), 526-536. https://doi.org/10.1002/mds.29355

Vancouver

Nowak B, Kozlowska E, Pawlik W, Fiszer A. Atrophin‐1 Function and Dysfunction in Dentatorubral–Pallidoluysian Atrophy. Movement Disorders. 2023;38(4):526-536. doi:10.1002/mds.29355

BibTeX
@article{Nowak2023,
  author = {Nowak, Bartosz and Kozlowska, Emilia and Pawlik, Weronika and Fiszer, Agnieszka},
  title = {Atrophin‐1 Function and Dysfunction in Dentatorubral–Pallidoluysian Atrophy},
  journal = {Movement Disorders},
  year = {2023},
  volume = {38},
  number = {4},
  pages = {526--536},
  doi = {10.1002/mds.29355}
}
Kostenlos starten →